Robert Pluenneke

Randomized Phase II Trial of Anthracycline-free and Anthracycline-containing Neoadjuvant Carboplatin Chemotherapy Regimens in Stage I–III Triple-negative Breast Cancer (NeoSTOP)

Priyanka Sharma, Bruce F. Kimler, Anne O’Dea et al. · Clinical Cancer Research · 2020 · 109 citations · Full text

Medicine, Oncology, Pharmacology +17

Impact of low versus negative estrogen/progesterone receptor status on clinico-pathologic characteristics and survival outcomes in HER2-negative breast cancer

Rachel Yoder, Bruce F. Kimler, Joshua M. Staley et al. · npj Breast Cancer · 2022 · 74 citations · Full text

Medicine, Oncology, Breast Oncology +13

Abstract S4-2: First Efficacy Results of a Randomized, Open-Label, Phase III Study of Adjuvant Doxorubicin Plus Cyclophosphamide, Followed by Docetaxel with or without Capecitabine, in High-Risk Early Breast Cancer

Joyce O’Shaughnessy, D Paul, Christopher Stokoe et al. · Cancer Research · 2010 · 39 citations

Medicine, Oncology, Pharmacology +17

Gemcitabine and Cisplatin for Patients with Metastatic or Recurrent Esophageal Carcinoma: A Southwest Oncology Group Study

Susan G. Urba, Kari Chansky, Peter J. VanVeldhuizen et al. · Investigational New Drugs · 2003 · 32 citations · Full text

Medicine, Oncology, Chemotherapy +13

Phase II Trial of Weekly Docetaxel/Gemcitabine as First-Line Chemotherapy in Patients with Locally Recurrent or Metastatic Breast Cancer

Joyce O’Shaughnessy, Robert Pluenneke, Jack J. Sternberg et al. · Clinical Breast Cancer · 2006 · 19 citations

Medicine, Oncology, Pharmacology +13